Gilead Sciences (NASDAQ: GILD) received a number of ratings updates from brokerages and research firms in the last week:

  • Gilead Sciences was upgraded by analysts at Lazard Capital from a “neutral” rating to a “buy” rating. They now have a $89.00 price target on the stock.
  • Gilead Sciences had its price target raised by analysts at Maxim Group from $70.00 to $83.00. They now have a “buy” rating on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at RBC Capital. They now have a $80.00 price target on the stock.
  • Gilead Sciences had its “hold” rating reaffirmed by analysts at Jefferies Group. They now have a $55.00 price target on the stock.
  • Gilead Sciences had its “outperform” rating reaffirmed by analysts at RBC Capital. They now have a $80.00 price target on the stock.

Shares of Gilead Sciences, Inc. traded down 1.68% during mid-day trading on Thursday, hitting $68.39. Gilead Sciences, Inc. has a one year low of $34.45 and a one year high of $70.39. The company has a market cap of $51.742 billion and a P/E ratio of 21.07.

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.